Nuvation Bio Inc. 2025 Annual Report: A Year of Strategic Progress and Pipeline Advancement

This summary breaks down Nuvation Bio Inc.'s performance for the fiscal year ended December 31, 2025. As a "smaller reporting company," Nuvation Bio operates with the agility of a focused biotech, aiming for significant breakthroughs in oncology. This approach carries both exciting potential and inherent risks. As of June 30, 2025, the company's market value reached approximately $497 million.

Business Overview: What Nuvation Bio Does Nuvation Bio is a clinical-stage oncology company that discovers, develops, and commercializes innovative therapies for patients with difficult-to-treat cancers. Its strategy involves building a diversified pipeline of novel small molecule and antibody-drug conjugate (ADC) candidates, using deep scientific expertise to address unmet medical needs. (An ADC is a targeted therapy that delivers potent drugs directly to cancer cells.)

Financial Performance: Investing in Innovation For fiscal year 2025, Nuvation Bio generated no significant revenue, which is typical for a clinical-stage biotech focused on research and development. The company reported a net loss of $185.3 million, reflecting substantial investment in its pipeline. Research and Development (R&D) expenses, the primary driver, totaled $158.7 million, an increase from $135.1 million in 2024. This increase highlights their commitment to advancing clinical programs. General and administrative expenses covered corporate operations and intellectual property efforts.

Management's Discussion and Analysis (MD&A) Highlights: Management's discussion highlights the company's strategic focus on advancing its oncology pipeline in 2025. The $185.3 million net loss stemmed primarily from $158.7 million in Research and Development (R&D) expenses, an increase from the prior year. This increase reflects NUV-400's progression into Phase 2 clinical trials, the start of Investigational New Drug (IND)-enabling studies for NUV-650, and ongoing investment in early-stage discovery programs. General and administrative expenses also contributed, supporting corporate operations and intellectual property efforts. As a clinical-stage company, Nuvation Bio generated no significant product revenue, consistent with its development stage.

Financial Health: Cash Runway and Liquidity Nuvation Bio ended 2025 with a strong cash position: $310.5 million in cash, cash equivalents, and marketable securities. This decreased from $495.8 million at the end of 2024, mainly due to R&D spending. The company carries no significant long-term debt, which provides financial flexibility. Management projects current cash reserves will fund planned operations and pipeline development into late 2027, assuming no unforeseen clinical setbacks or significant new business development activities. This cash runway is critical for a company at this stage, enabling it to reach key clinical milestones.

Major Wins and Pipeline Progress: Nuvation Bio achieved significant pipeline progress in 2025:

• NUV-400 (Lead Candidate): This novel small molecule inhibitor, targeting a specific cancer-causing pathway, successfully completed its Phase 1 dose-escalation study in solid tumors. The company presented positive preliminary data, including early signs of efficacy and a favorable safety profile, at the American Society of Clinical Oncology (ASCO) annual meeting in June 2025. Nuvation Bio initiated a Phase 2 study for NUV-400 in non-small cell lung cancer (NSCLC) in Q4 2025, expecting initial data in late 2026.
• NUV-650 (Preclinical): Nuvation Bio filed an Investigational New Drug (IND) application for NUV-650, an antibody-drug conjugate (ADC) designed to target a novel tumor antigen, in Q3 2025. This filing marks its transition from preclinical development to potential human trials, with a Phase 1 study anticipated to begin in early 2026.
• Strategic Research: The company expanded its early-stage research efforts, identifying two new promising drug discovery targets and reinforcing its long-term pipeline strategy.

Risk Factors: Key Risks to Consider Investing in Nuvation Bio involves significant risks inherent to the biotech industry:

• Clinical Trial Success: Success for NUV-400 and other pipeline candidates is not guaranteed. Clinical trials can fail at any stage due to lack of efficacy or unacceptable safety profiles.
• Regulatory Approval: Even with positive clinical data, the FDA or other regulatory bodies may not approve Nuvation Bio's product candidates.
• Competition: The oncology market is highly competitive, with numerous large pharmaceutical companies and other biotechs developing similar or alternative therapies.
• Funding: Despite current cash reserves, Nuvation Bio will likely need additional capital for later-stage clinical trials and potential commercialization. Failure to secure funding could delay or halt development.
• Intellectual Property: The company's success depends on its ability to protect its intellectual property, a challenging task in the pharmaceutical industry.

Competitive Position: Nuvation Bio aims to differentiate itself through its targeted approach to specific cancer-causing pathways and its innovative antibody-drug conjugate (ADC) platform. While competing with established players like AstraZeneca and Novartis, its focus on novel mechanisms of action could provide a competitive edge if clinical data proves superior.

Leadership and Strategy: Nuvation Bio's leadership team remained stable throughout 2025, maintaining a focus on efficient R&D execution and prudent financial management. Their strategy emphasizes advancing NUV-400 through its next clinical stages, initiating human trials for NUV-650, and selectively pursuing strategic partnerships to accelerate development or expand market reach.

Future Outlook: Looking ahead to 2026, Nuvation Bio's primary goals are:

• Reporting initial Phase 2 data for NUV-400 in NSCLC.
• Initiating the Phase 1 clinical trial for NUV-650.
• Continuing to build out its preclinical pipeline.

These milestones will critically indicate the company's progress and potential value creation. The company remains committed to bringing transformative cancer therapies to patients, navigating the complex drug development landscape with a clear strategic vision.